Slc28a2, also known as the gene encoding human concentrative nucleoside transporter 2 (hCNT2), plays a major role in the intestinal absorption of naturally occurring nucleosides as well as some nucleoside analog drugs. It is involved in the nucleobase-containing compound metabolic process and is part of the solute carrier 28 family [4,5,6].

In rectal cancer patients undergoing neoadjuvant concurrent chemoradiotherapy (CCRT), high SLC28A2 immunoexpression is linked to an advanced stage, poor response to CCRT, and worse patient survival, making it a valuable predictive and prognostic marker [1]. In Han Chinese, common variants in the SLC28A2 gene are associated with serum uric acid level, hyperuricemia, and gout [2]. In hepatitis C treatment, the SLC28A2 rs11854484 genotype predicts clinically significant anaemia, helping to identify patients with better tolerance of triple therapy [3].

In conclusion, Slc28a2 is crucial for nucleoside transport and metabolism. Its role in diseases such as rectal cancer, hyperuricemia, gout, and hepatitis C-related anaemia has been revealed through various studies. Understanding Slc28a2 can potentially lead to better disease prediction, prognosis, and treatment strategies in these disease areas.